Replacement of Chalcone-Ethers with Chalcone-Thioethers as Potent and Highly Selective Monoamine Oxidase-B Inhibitors and Their Protein-Ligand Interactions.
MAO-B
ROS
chalcone
cytotoxicity
molecular dynamics
reversibility
selectivity
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
11 Nov 2021
11 Nov 2021
Historique:
received:
18
10
2021
revised:
01
11
2021
accepted:
09
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
To develop new potent and highly selective MAO-B inhibitors from chalcone-thioethers, eleven chalcones-thioethers were synthesized and their monoamine oxidase (MAO) inhibition, kinetics, reversibility, and cytotoxicity of lead compounds were analyzed. Molecular dynamics were carried out to investigate the interactions. Compound
Identifiants
pubmed: 34832930
pii: ph14111148
doi: 10.3390/ph14111148
pmc: PMC8623647
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Amrita Vishwa Vidyapeetham University
ID : K-PHAR-20-628
Organisme : Taif University Researchers Supporting Program
ID : TURSP-2020/68
Références
Eur J Med Chem. 2016 May 23;114:162-9
pubmed: 26974383
J Neural Transm (Vienna). 2018 Nov;125(11):1519-1551
pubmed: 29637260
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Bioorg Chem. 2018 Oct;80:86-93
pubmed: 29890362
Expert Opin Ther Pat. 2012 Jul;22(7):759-801
pubmed: 22702491
J Med Chem. 2015 Sep 10;58(17):6717-32
pubmed: 25915162
Eur J Med Chem. 2020 Nov 1;205:112650
pubmed: 32920430
Bioorg Chem. 2019 Dec;93:103335
pubmed: 31606547
Int J Biol Macromol. 2017 Nov;104(Pt A):1321-1329
pubmed: 28577983
Medchemcomm. 2018 Sep 25;9(11):1871-1881
pubmed: 30568755
Chem Rev. 2017 Jun 28;117(12):7762-7810
pubmed: 28488435
Eur J Med Chem. 2013 Jan;59:91-100
pubmed: 23207410
Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
ACS Omega. 2021 Sep 01;6(36):23399-23411
pubmed: 34549139
Bioorg Chem. 2015 Oct;62:22-9
pubmed: 26189013
Curr Pharm Des. 2013;19(14):2529-39
pubmed: 23116392
Acta Crystallogr Sect E Struct Rep Online. 2008 Jun 13;64(Pt 7):o1263
pubmed: 21202897
Science. 1986 Feb 28;231(4741):987-9
pubmed: 3080808
Drug Des Devel Ther. 2020 Jan 28;14:371-393
pubmed: 32099324
ACS Comb Sci. 2020 Nov 9;22(11):592-599
pubmed: 33047950
Bioorg Med Chem. 2015 Feb 1;23(3):471-9
pubmed: 25555734
Chem Biol Drug Des. 2015 Jun;85(6):685-95
pubmed: 25346162
J Med Chem. 2009 May 14;52(9):2818-24
pubmed: 19378991
J Pharm Pharmacol. 2020 Jul;72(7):916-926
pubmed: 32246471
Lancet Neurol. 2009 Dec;8(12):1128-39
pubmed: 19909911
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Nat Rev Neurosci. 2006 Apr;7(4):295-309
pubmed: 16552415
Mar Drugs. 2019 Apr 13;17(4):
pubmed: 31013932
CNS Neurol Disord Drug Targets. 2019;18(6):432-445
pubmed: 31187716
Eur J Med Chem. 2003 Mar;38(3):223-32
pubmed: 12667689
J Med Chem. 2020 Feb 13;63(3):1361-1387
pubmed: 31917923
Arch Pharm (Weinheim). 2019 Nov;352(11):e1900177
pubmed: 31478569
J Enzyme Inhib Med Chem. 2019 Dec;34(1):863-876
pubmed: 30915862
Nucleic Acids Res. 2019 Jul 2;47(W1):W357-W364
pubmed: 31106366
Neuropsychiatr Dis Treat. 2008 Aug;4(4):743-57
pubmed: 19043519
Expert Opin Ther Pat. 2019 May;29(5):385-406
pubmed: 31030616
Bioorg Chem. 2019 Mar;83:317-325
pubmed: 30396116
Mov Disord. 2011 May;26(6):1049-55
pubmed: 21626550
Parkinsonism Relat Disord. 2000 Jan;6(1):25-47
pubmed: 18591148
ChemMedChem. 2016 Dec 16;11(24):2649-2655
pubmed: 27902880
J Mol Graph Model. 2006 Oct;25(2):247-60
pubmed: 16458552